Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Derman BA, et al. Among authors: kubicki t. Blood Cancer J. 2024 May 29;14(1):87. doi: 10.1038/s41408-024-01045-3. Blood Cancer J. 2024. PMID: 38811560 Free PMC article. Clinical Trial.
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Kubicki T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Kubicki T, et al. Pol Arch Intern Med. 2024 May 28;134(5):16749. doi: 10.20452/pamw.16749. Epub 2024 May 14. Pol Arch Intern Med. 2024. PMID: 38747414 Free article. Clinical Trial. No abstract available.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Kubicki T, Dytfeld D, Barnidge DR, Sakrikar D, Przybyłowicz-Chalecka A, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek AA, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil LA, Puła B, Szukalski L, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T Prof, Jiang K, Cooperrider JH, Jakubowiak AJ, Derman BA. Kubicki T, et al. Blood. 2024 May 7:blood.2024024041. doi: 10.1182/blood.2024024041. Online ahead of print. Blood. 2024. PMID: 38713888
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk-Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland.
Kałużewski T, Kubiak I, Bednarek M, Sałamunia J, Kucharska D, Kępczyński Ł, Stempień M, Kubicki T, Trzciński R, Gordon-Sönmez Z, Bartosińska-Dyc A, Gach A, Kałużewski B. Kałużewski T, et al. Among authors: kubicki t. Int J Mol Sci. 2023 Aug 24;24(17):13178. doi: 10.3390/ijms241713178. Int J Mol Sci. 2023. PMID: 37685988 Free PMC article.
G6PD deficiency-does it alter the course of COVID-19 infections?
Au TY, Wiśniewski OW, Benjamin S, Kubicki T, Dytfeld D, Gil L. Au TY, et al. Among authors: kubicki t. Ann Hematol. 2023 Jul;102(7):1629-1636. doi: 10.1007/s00277-023-05164-y. Epub 2023 Mar 11. Ann Hematol. 2023. PMID: 36905446 Free PMC article. Review.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: kubicki t. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.
Lewandowski K, Kopydłowska A, Kanduła Z, Sankowski B, Machnicki M, Barańska M, Gwóźdź-Bąk K, Kubicki T, Płotka A, Przysiecka Ł, Dworacki G, Kozłowski P, Stokłosa T. Lewandowski K, et al. Among authors: kubicki t. J Cell Mol Med. 2023 Jan;27(2):299-303. doi: 10.1111/jcmm.17647. Epub 2023 Jan 5. J Cell Mol Med. 2023. PMID: 36606310 Free PMC article.
32 results